Check the specific product packaging for storage instructions, as formulations can vary
When sex emerged as a significant factor, separate ANOVAs were performed for males and females
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin Glucagon-like peptide 1 (GLP-1) is a powerful hormone that significantly decreases blood glucose (sugar) levels
Baseline health Where your health stands at the beginning of treatment matters
These conditions often go hand in hand, fueling complications such as cardiovascular disease, fatty liver disease, and metabolic syndrome
Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
